**Background**

Cytokine release syndrome (CRS) is a common and life-threatening toxicity directly related to new targeted therapies for oncohematological diseases. Although the optimal therapy for CRS remains unknown, tocilizumab has demonstrated success.

**Materials & Methods**

- Retrospective observational study in a single center.
- Onco-hematologic patients who received tocilizumab for CRS treatment from 2019 to 2021 were studied.
- Effectiveness evaluation: CRS resolution after tocilizumab treatment was evaluated.
- CRS severity based on the American Society for Transplantation and Cellular Therapies grading scale for CRS, was compared between the groups of patients with different onco-hematologic diagnosis and different targeted therapies.

**Results**

**TOCILIZUMAB TREATMENT AND EFFECTIVENESS EVALUATION**

- Tocilizumab median dose was 8.0 (5.3-10.4) mg/kg
- Twelve patients (25.5%) required a second tocilizumab dose
- CRS resolved in 100% of patients

**Conclusions**

- Tocilizumab is an effective treatment in CRS after new targeted therapies in onco-hematological patients.
- Severity of CRS seems to be higher in patients with diagnosis of lymphoma and in those treated with bispecific antibodies or HSTC.

**References**